|
|
||||||||||
|
J Am Coll Cardiol, 2003; 41:961-965, doi:10.1016/S0735-1097(02)03014-0 © 2003 by the American College of Cardiology Foundation |
* Department of Cardiovascular Medicine, The Cleveland Clinic Foundation, Cleveland, Ohio, USA
Manuscript received May 6, 2002; revised manuscript received October 3, 2002, accepted November 11, 2002.
* Reprint requests and correspondence: Dr. Eric J. Topol, Department of Cardiovascular Medicine, Desk F25, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, Ohio 44195, USA.
topole{at}ccf.org
OBJECTIVES: This study was designed to determine if aspirin resistance is associated with clinical events.
BACKGROUND: Aspirin resistance, defined by platelet function testing and presumed clinical unresponsiveness to aspirin, has been previously reported by our group and others. However, little information exists linking the laboratory documentation of aspirin resistance and long-term clinical events.
METHODS: We prospectively enrolled 326 stable cardiovascular patients from 1997 to 1999 on aspirin (325 mg/day for
7 days) and no other antiplatelet agents. We tested for aspirin sensitivity by optical platelet aggregation using adenosine diphosphate (ADP) and arachidonic acid (AA). The primary outcome was the composite of death, myocardial infarction (MI), or cerebrovascular accident (CVA). Mean follow-up was 679 ± 185 days. Aspirin resistance was defined as a mean aggregation of
70% with 10 µM ADP and
20% with 0.5 mg/ml AA.
RESULTS: Of the patients studied, 17 (5.2%) were aspirin resistant and 309 (94.8%) were not aspirin resistant. During follow-up, aspirin resistance was associated with an increased risk of death, MI, or CVA compared with patients who were aspirin sensitive (24% vs. 10%, hazard ratio [HR] 3.12, 95% confidence interval [CI] 1.10 to 8.90, p = 0.03). Stratified multivariate analyses identified platelet count, age, heart failure, and aspirin resistance to be independently associated with major adverse long-term outcomes (HR for aspirin resistance 4.14, 95% CI 1.42 to 12.06, p = 0.009).
CONCLUSIONS: This study demonstrates the natural history of aspirin resistance in a stable population, documenting a greater than threefold increase in the risk of major adverse events associated with aspirin resistance.
| ||||||||||||||
This article has been cited by other articles:
![]() |
A. M. Gori, R. Marcucci, A. Migliorini, R. Valenti, G. Moschi, R. Paniccia, P. Buonamici, G. F. Gensini, R. Vergara, R. Abbate, et al. Incidence and Clinical Impact of Dual Nonresponsiveness to Aspirin and Clopidogrel in Patients With Drug-Eluting Stents J. Am. Coll. Cardiol., August 26, 2008; 52(9): 734 - 739. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Guthikonda, C. L. Alviar, M. Vaduganathan, M. Arikan, A. Tellez, T. DeLao, J. F. Granada, J.-F. Dong, N. S. Kleiman, and E. I. Lev Role of Reticulated Platelets and Platelet Size Heterogeneity on Platelet Activity After Dual Antiplatelet Therapy With Aspirin and Clopidogrel in Patients With Stable Coronary Artery Disease J. Am. Coll. Cardiol., August 26, 2008; 52(9): 743 - 749. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. E. Herrera-Galeano, D. M. Becker, A. F. Wilson, L. R. Yanek, P. Bray, D. Vaidya, N. Faraday, and L. C. Becker A Novel Variant in the Platelet Endothelial Aggregation Receptor-1 Gene Is Associated With Increased Platelet Aggregability Arterioscler. Thromb. Vasc. Biol., August 1, 2008; 28(8): 1484 - 1490. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. T. Newsome, M. A. Kutcher, and R. L. Royster Coronary Artery Stents: Part I. Evolution of Percutaneous Coronary Intervention Anesth. Analg., August 1, 2008; 107(2): 552 - 569. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Yano, T. Ohmori, S. Hoshide, S. Madoiwa, K. Yamamoto, T. Katsuki, T. Mitsuhashi, J. Mimuro, K. Shimada, K. Kario, et al. Determinants of thrombin generation, fibrinolytic activity, and endothelial dysfunction in patients on dual antiplatelet therapy: involvement of factors other than platelet aggregability in Virchow's triad Eur. Heart J., July 2, 2008; 29(14): 1729 - 1738. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. W. Kamphuisen Thrombogenicity in patients with percutaneous coronary artery intervention and dual antiplatelet treatment Eur. Heart J., July 2, 2008; 29(14): 1699 - 1700. [Full Text] [PDF] |
||||
![]() |
N. Zimmermann, E. Gams, and T. Hohlfeld Aspirin in coronary artery bypass surgery: new aspects of and alternatives for an old antithrombotic agent. Eur. J. Cardiothorac. Surg., July 1, 2008; 34(1): 93 - 108. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Nappi Benefits and limitations of current antiplatelet therapies Am. J. Health Syst. Pharm., July 1, 2008; 65(13_Supplement_5): S5 - S10. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. J. Price New antiplatelet therapies in development Am. J. Health Syst. Pharm., July 1, 2008; 65(13_Supplement_5): S11 - S15. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Patrono, C. Baigent, J. Hirsh, and G. Roth Antiplatelet Drugs: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) Chest, June 1, 2008; 133(6_suppl): 199S - 233S. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Y. Gasparyan, T. Watson, and G. Y.H. Lip The Role of Aspirin in Cardiovascular Prevention: Implications of Aspirin Resistance J. Am. Coll. Cardiol., May 13, 2008; 51(19): 1829 - 1843. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Aradi, A. Konyi, L. Palinkas, T. Berki, T. Pinter, T. Tahin, I. Horvath, L. Papp, and A. Komocsi Thienopyridine Therapy Influences Late Outcome After Coronary Stent Implantation Angiology, May 1, 2008; 59(2): 172 - 178. [Abstract] [PDF] |
||||
![]() |
N. Zimmermann, M. Kurt, J. Winter, E. Gams, F. Wenzel, and T. Hohlfeld Detection and duration of aspirin resistance after coronary artery bypass grafting. J. Thorac. Cardiovasc. Surg., April 1, 2008; 135(4): 947 - 948. [Full Text] [PDF] |
||||
![]() |
D. J. Kereiakes and P. A. Gurbel Peri-Procedural Platelet Function and Platelet Inhibition in Percutaneous Coronary Intervention J. Am. Coll. Cardiol. Intv., April 1, 2008; 1(2): 111 - 121. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Patrono and B. Rocca Aspirin: Promise and Resistance in the New Millennium Arterioscler. Thromb. Vasc. Biol., March 1, 2008; 28(3): s25 - s32. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. M. Gengo, M. Rainka, M. Robson, M. F. Gengo, A. Forrest, M. Hourihane, and V. Bates Prevalence of Platelet Nonresponsiveness to Aspirin in Patients Treated for Secondary Stroke Prophylaxis and in Patients With Recurrent Ischemic Events J. Clin. Pharmacol., March 1, 2008; 48(3): 335 - 343. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Manrique, G. Lastra, J. Palmer, M. Gardner, and J. R. Sowers Review: Aspirin and Diabetes Mellitus: revisiting an old player Therapeutic Advances in Cardiovascular Disease, February 1, 2008; 2(1): 37 - 42. [Abstract] [PDF] |
||||
![]() |
Y.-W. Lee, Y.-H. Cho, Y.-H. Kim, J.-S. Na, H. B. Shin, C.-S. Ki, T.-Y. Choi, and Y. K. Lee Aspirin Non-Responsiveness in Korean Subjects on Dual Anti-Platelet Treatment Determined by Two Different Platelet Function Assays Ann. Clin. Lab. Sci., January 1, 2008; 38(2): 126 - 131. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. F. Storey Variability of response to antiplatelet therapy Eur. Heart J. Suppl., January 1, 2008; 10(suppl_A): A21 - A27. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Gachet and B. Aleil Testing antiplatelet therapy Eur. Heart J. Suppl., January 1, 2008; 10(suppl_A): A28 - A34. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. DiChiara, K. P. Bliden, U. S. Tantry, M. S. Hamed, M. J. Antonino, T. A. Suarez, O. Bailon, A. Singla, and P. A. Gurbel The Effect of Aspirin Dosing on Platelet Function in Diabetic and Nondiabetic Patients: An Analysis From the Aspirin-Induced Platelet Effect (ASPECT) Study Diabetes, December 1, 2007; 56(12): 3014 - 3019. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. A. Gurbel, R. C. Becker, K. G. Mann, S. R. Steinhubl, and A. D. Michelson Platelet Function Monitoring in Patients With Coronary Artery Disease J. Am. Coll. Cardiol., November 6, 2007; 50(19): 1822 - 1834. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Wan, N. Shukla, G. D. Angelini, A. P.C. Yim, J. L. Johnson, and J. Y. Jeremy Nitric oxide-donating aspirin (NCX 4016) inhibits neointimal thickening in a pig model of saphenous vein-carotid artery interposition grafting: A comparison with aspirin and morpholinosydnonimine (SIN-1). J. Thorac. Cardiovasc. Surg., October 1, 2007; 134(4): 1033 - 1039. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. D. Snoep, M. M. C. Hovens, J. C. J. Eikenboom, J. G. van der Bom, and M. V. Huisman Association of Laboratory-Defined Aspirin Resistance With a Higher Risk of Recurrent Cardiovascular Events: A Systematic Review and Meta-analysis Arch Intern Med, August 13, 2007; 167(15): 1593 - 1599. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Van de Werf Dual antiplatelet therapy in high-risk patients Eur. Heart J. Suppl., August 1, 2007; 9(suppl_D): D3 - D9. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Husted New developments in oral antiplatelet therapy Eur. Heart J. Suppl., August 1, 2007; 9(suppl_D): D20 - D27. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Lordkipanidze, C. Pharand, E. Schampaert, J. Turgeon, D. A. Palisaitis, and J. G. Diodati A comparison of six major platelet function tests to determine the prevalence of aspirin resistance in patients with stable coronary artery disease Eur. Heart J., July 2, 2007; 28(14): 1702 - 1708. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Faraday, L. R. Yanek, R. Mathias, J. E. Herrera-Galeano, D. Vaidya, T. F. Moy, M. D. Fallin, A. F. Wilson, P. F. Bray, L. C. Becker, et al. Heritability of Platelet Responsiveness to Aspirin in Activation Pathways Directly and Indirectly Related to Cyclooxygenase-1 Circulation, May 15, 2007; 115(19): 2490 - 2496. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. A. Meadows and D. L. Bhatt Clinical Aspects of Platelet Inhibitors and Thrombus Formation Circ. Res., May 11, 2007; 100(9): 1261 - 1275. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. O. Maree and D. J. Fitzgerald Variable Platelet Response to Aspirin and Clopidogrel in Atherothrombotic Disease Circulation, April 24, 2007; 115(16): 2196 - 2207. [Full Text] [PDF] |
||||
![]() |
B. T. Ivandic, E. Giannitsis, P. Schlick, P. Staritz, H. A. Katus, and T. Hohlfeld Determination of Aspirin Responsiveness by Use of Whole Blood Platelet Aggregometry Clin. Chem., April 1, 2007; 53(4): 614 - 619. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Undas, K. E. Brummel-Ziedins, and K. G. Mann Antithrombotic properties of aspirin and resistance to aspirin: beyond strictly antiplatelet actions Blood, March 15, 2007; 109(6): 2285 - 2292. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. J. Fitzgerald and A. Maree Aspirin and Clopidogrel Resistance Hematology, January 1, 2007; 2007(1): 114 - 120. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Pfisterer, H. P. Brunner-La Rocca, P. T. Buser, P. Rickenbacher, P. Hunziker, C. Mueller, R. Jeger, F. Bader, S. Osswald, C. Kaiser, et al. Late Clinical Events After Clopidogrel Discontinuation May Limit the Benefit of Drug-Eluting Stents: An Observational Study of Drug-Eluting Versus Bare-Metal Stents J. Am. Coll. Cardiol., December 19, 2006; 48(12): 2584 - 2591. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. D. Michelson, A. L. Frelinger, and M. I. Furman Resistance to antiplatelet drugs Eur. Heart J. Suppl., October 1, 2006; 8(suppl_G): G53 - G58. [Abstract] [Full Text] [PDF] |
||||
![]() |
S.-H. Hung, W. Zhang, R. A. Pixley, B. A. Jameson, Y. C. Huang, R. F. Colman, and R. W. Colman New Insights from the Structure-Function Analysis of the Catalytic Region of Human Platelet Phosphodiesterase 3A: A ROLE FOR THE UNIQUE 44-AMINO ACID INSERT J. Biol. Chem., September 29, 2006; 281(39): 29236 - 29244. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. H. Hennekens, O. Sechenova, D. Hollar, and V. L. Serebruany Dose of Aspirin in the Treatment and Prevention of Cardiovascular Disease: Current and Future Directions. Journal of Cardiovascular Pharmacology and Therapeutics, September 1, 2006; 11(3): 170 - 176. [Abstract] [PDF] |
||||
![]() |
D. Cox, A. O. Maree, M. Dooley, R. Conroy, M. F. Byrne, and D. J. Fitzgerald Effect of Enteric Coating on Antiplatelet Activity of Low-Dose Aspirin in Healthy Volunteers Stroke, August 1, 2006; 37(8): 2153 - 2158. [Abstract] [Full Text] [PDF] |
||||
![]() |
U. S. Tantry, K. P. Bliden, and P. A. Gurbel Reply J. Am. Coll. Cardiol., June 20, 2006; 47(12): 2566 - 2566. [Full Text] [PDF] |
||||
![]() |
L. H Cavallari, C. M Helgason, L. D Brace, M. A. Viana, and E. A Nutescu Sex Difference in the Antiplatelet Effect of Aspirin in Patients with Stroke Ann. Pharmacother., May 1, 2006; 40(5): 812 - 817. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. M. Becker, J. Segal, D. Vaidya, L. R. Yanek, J. E. Herrera-Galeano, P. F. Bray, T. F. Moy, L. C. Becker, and N. Faraday Sex Differences in Platelet Reactivity and Response to Low-Dose Aspirin Therapy JAMA, March 22, 2006; 295(12): 1420 - 1427. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. H. Wang, D. L. Bhatt, and E. J. Topol Aspirin and clopidogrel resistance: an emerging clinical entity Eur. Heart J., March 2, 2006; 27(6): 647 - 654. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. I. Lev, R. T. Patel, K. J. Maresh, S. Guthikonda, J. Granada, T. DeLao, P. F. Bray, and N. S. Kleiman Aspirin and Clopidogrel Drug Response in Patients Undergoing Percutaneous Coronary Intervention: The Role of Dual Drug Resistance J. Am. Coll. Cardiol., January 3, 2006; 47(1): 27 - 33. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. S. Poston, C. White, J. Gu, J. Brown, J. Gammie, R. N. Pierson, A. Lee, I. Connerney, T. Avari, R. Christenson, et al. Aprotinin Shows Both Hemostatic and Antithrombotic Effects During Off-Pump Coronary Artery Bypass Grafting Ann. Thorac. Surg., January 1, 2006; 81(1): 104 - 111. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. I. Lev, R. T. Patel, K. J. Maresh, S. Guthikonda, J. Granada, T. DeLao, P. F. Bray, and N. S. Kleiman Aspirin and Clopidogrel Drug Response in Patients Undergoing Percutaneous Coronary Intervention: The Role of Dual Drug Resistance J. Am. Coll. Cardiol., December 13, 2005; (2005) j.jacc.2005.08.058v1. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. A. Gurbel, K. P. Bliden, W. Samara, J. A. Yoho, K. Hayes, M. Z. Fissha, and U. S. Tantry Clopidogrel Effect on Platelet REactivity in Patients With Stent Thrombosis: Results of the CREST Study J. Am. Coll. Cardiol., November 15, 2005; 46(10): 1827 - 1832. [Abstract] [Full Text] [PDF] |
||||
![]() |
U. S. Tantry, K. P. Bliden, and P. A. Gurbel Overestimation of Platelet Aspirin Resistance Detection by Thrombelastograph Platelet Mapping and Validation by Conventional Aggregometry Using Arachidonic Acid Stimulation J. Am. Coll. Cardiol., November 1, 2005; 46(9): 1705 - 1709. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. O. Maree, R. J. Curtin, M. Dooley, R. M. Conroy, P. Crean, D. Cox, and D. J. Fitzgerald Platelet Response to Low-Dose Enteric-Coated Aspirin in Patients With Stable Cardiovascular Disease J. Am. Coll. Cardiol., October 4, 2005; 46(7): 1258 - 1263. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Fosslien Cardiovascular Complications of Non-Steroidal Anti-Inflammatory Drugs Ann. Clin. Lab. Sci., October 1, 2005; 35(4): 347 - 385. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. J. Mason, A. K. Jacobs, and J. E. Freedman Aspirin Resistance and Atherothrombotic Disease J. Am. Coll. Cardiol., September 20, 2005; 46(6): 986 - 993. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. J. Angiolillo, A. Fernandez-Ortiz, E. Bernardo, C. Ramirez, M. Sabate, P. Jimenez-Quevedo, R. Hernandez, R. Moreno, J. Escaned, F. Alfonso, et al. Platelet Function Profiles in Patients With Type 2 Diabetes and Coronary Artery Disease on Combined Aspirin and Clopidogrel Treatment Diabetes, August 1, 2005; 54(8): 2430 - 2435. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. J. Saseen ASHP Therapeutic Position Statement on the Daily Use of Aspirin for Preventing Cardiovascular Events Am. J. Health Syst. Pharm., July 1, 2005; 62(13): 1398 - 1405. [Full Text] [PDF] |
||||
![]() |
H Mani, B Luxembourg, C Klaffling, M Erbe, and E Lindhoff-Last Use of native or platelet count adjusted platelet rich plasma for platelet aggregation measurements J. Clin. Pathol., July 1, 2005; 58(7): 747 - 750. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Wenaweser, J. Dorffler-Melly, K. Imboden, S. Windecker, M. Togni, B. Meier, A. Haeberli, and O. M. Hess Stent Thrombosis Is Associated With an Impaired Response to Antiplatelet Therapy J. Am. Coll. Cardiol., June 7, 2005; 45(11): 1748 - 1752. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. R. Steinhubl, R. Charnigo, and D. J. Moliterno Resistance to Antiplatelet Resistance: Is it Justified? J. Am. Coll. Cardiol., June 7, 2005; 45(11): 1757 - 1758. [Full Text] [PDF] |
||||
![]() |
P. Wenaweser, C. Rey, F. R. Eberli, M. Togni, D. Tuller, S. Locher, A. Remondino, C. Seiler, O. M. Hess, B. Meier, et al. Stent thrombosis following bare-metal stent implantation: success of emergency percutaneous coronary intervention and predictors of adverse outcome Eur. Heart J., June 2, 2005; 26(12): 1180 - 1187. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Papp, V. Havasi, J. Bene, K. Komlosi, L. Czopf, E. Magyar, C. Feher, G. Feher, B. Horvath, Z. Marton, et al. Glycoprotein IIIA Gene (PlA) Polymorphism and Aspirin Resistance: Is There Any Correlation? Ann. Pharmacother., June 1, 2005; 39(6): 1013 - 1018. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. R. Bates and W. C. Lau Controversies in Antiplatelet Therapy for Patients With Cardiovascular Disease Circulation, May 3, 2005; 111(17): e267 - e271. [Full Text] [PDF] |